Literature DB >> 22173490

Tumor antigen-pulsed CD8α(+) dendritic cells induce T cell-mediated graft-versus-tumor effect in vitro.

Ning Na1, Kang Chen2, Jian Zhang1, Shanyang He3, Qiang Fu4, Beili Zhu5, Kaiyuan Cao4, Lin Xu6.   

Abstract

The graft-versus-tumor (GVT) effect of T cells induced by tumor antigen-pulsed CD8α(+) dendritic cells (DCs) in vitro was investigated in this study. Immature CD8α(+) DCs were prepared from C57BL/6 (H-2(b)) bone marrow cells by using a cytokine cocktail. On the 3rd day of culture, CD8α(+) DCs were pulsed by allogeneic (Balb/c, H-2(d)) EL9611 leukemia antigen, or RM-1 syngeneic prostate cancer antigen, with the concentration series of 0, 2.5, 5.0, 10.0, 20.0 μg/mL, respectively, then antigen-loaded immature CD8α(+) DCs were co-cultured with syngeneic T cells according to the DC/T ratio of 1:1, 2:1 and 4:1. T cell proliferation was measured by MTT assay. Cytokines including interferon gamma (IFN-γ) and interleukin-10 (IL-10) in CD8α(+) DCs and T co-culture supernatant were detected by using ELISA. Cytotoxic effect of antigen-specific T cells was tested by LDH release assay. Conventional mature DCs (mDCs) induced from C57BL/6 (H-2(b)) bone marrow cells by using granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-4 (IL-4) served as a control. The results showed that the proliferative activity of T cells stimulated by CD8α(+) DCs loaded with allogeneic or syngeneic tumor antigen was augmented with the CD8α(+) DC/T ratio increased (P<0.05). When antigen concentration ≤ 5 μg/mL and CD8α(+) DC/T ratio ≤ 2:1, the ability of CD8α(+) DCs to stimulate T cell proliferation was higher than mDC control in allogeneic tumor antigen-pulsed groups (P<0.05), but not in syngeneic tumor antigen-pulsed groups (P>0.05). The level of IFN-γ and IL-10 in CD8α(+) DCs and T cell co-culture supernatant were increased in both allogeneic and syngeneic antigen-pulsed groups (P<0.05), and the cytokine level was higher in allogeneic antigen-pulsed groups than in syngeneic antigen groups when the CD8α(+) DC/T was 1:1 or 2:1 (P<0.05). There existed a negative correlation between the level of IL-10 and T cell proliferation. T cell cytotoxicity assay showed that when CD8α(+) DCs were pulsed with allogeneic tumor antigen, the maximal T cell killing efficiency could reach (100±7.7)%, whereas syngeneic tumor antigen-pulsed group had only (65.0±3.4)%. It was concluded that syngeneic and allogeneic tumor antigen-pulsed immature CD8α(+) DCs could stimulate T cells to exert the GVT effect in vitro, and the GVT effect was more obvious with allogeneic tumor antigen than with syngeneic tumor antigen. The optimal condition was low allogeneic tumor antigen pulsation (≤ 5 μg/mL) and low CD8α(+) DC/T ratio (1:1 and 2:1).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22173490     DOI: 10.1007/s11596-011-0668-9

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  19 in total

1.  Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.

Authors:  Shoji Asakura; Daigo Hashimoto; Shuichiro Takashima; Haruko Sugiyama; Yoshinobu Maeda; Koichi Akashi; Mitsune Tanimoto; Takanori Teshima
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

Review 2.  Origin, precursors and differentiation of mouse dendritic cells.

Authors:  Carlos Ardavín
Journal:  Nat Rev Immunol       Date:  2003-07       Impact factor: 53.106

3.  Predominant immature CD8alpha+ dendritic cells prevent graft-vs.-host disease but do not increase the risk of leukemia recurrence.

Authors:  Lin Xu; Lianning Duan; Kaiyuan Cao; Guangqing Yuan; Yanwen Peng; Xiaorong Huang; Peng Xiang; Shunong Li
Journal:  Eur J Haematol       Date:  2007-01-23       Impact factor: 2.997

4.  [Establishment and biological characterization of a transplantable BALB/c mouse erythroblastic leukemia model].

Authors:  S Ding; J Chu; J Zhao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  1998-12

Review 5.  Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.

Authors:  Steven C Goldstein; David L Porter
Journal:  Expert Rev Hematol       Date:  2010-06       Impact factor: 2.929

6.  Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4.

Authors:  Saroj K Basak; Airi Harui; Marina Stolina; Sherven Sharma; Kohnosuke Mitani; Steven M Dubinett; Michael D Roth
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

7.  Optimal in vitro culture conditions for murine predominant immature CD8a+ dendritic cells.

Authors:  Ning Na; Lin Xu; Kai-yuan Cao; Yun Luo; Guang-qing Yuan; Peng Xiang; Liang-qing Hong; Shu-nong Li
Journal:  Chin Med J (Engl)       Date:  2009-02-05       Impact factor: 2.628

8.  Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells.

Authors:  Akihiko Matsumoto; Kyoko Haraguchi; Tsuyoshi Takahashi; Takeshi Azuma; Yoshinobu Kanda; Kyoichi Tomita; Mineo Kurokawa; Seishi Ogawa; Koki Takahashi; Shigeru Chiba; Tadaichi Kitamura
Journal:  Int J Urol       Date:  2007-04       Impact factor: 3.369

Review 9.  Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease.

Authors:  Robbert Spaapen; Tuna Mutis
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

10.  CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens.

Authors:  Mariolina Salio; Michael J Palmowski; Ann Atzberger; Ian F Hermans; Vincenzo Cerundolo
Journal:  J Exp Med       Date:  2004-02-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.